These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 31944872)

  • 1. World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application.
    McDonell J; Costello K; Laurson-Doube J; Rijke N; Giovannoni G; Banwell B; Baneke P
    Mult Scler; 2020 Feb; 26(2):153-158. PubMed ID: 31944872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.
    Zimmermann M; Brouwer E; Tice JA; Seidner M; Loos AM; Liu S; Chapman RH; Kumar V; Carlson JJ
    CNS Drugs; 2018 Dec; 32(12):1145-1157. PubMed ID: 30141001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications.
    Baxi SM; Beall R; Yang J; Mackey TK
    Global Health; 2019 Sep; 15(1):57. PubMed ID: 31533850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis.
    Sternberg Z; Leung C; Sternberg D; Yu J; Hojnacki D
    Cardiovasc Ther; 2014 Apr; 32(2):33-9. PubMed ID: 24119301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis.
    Marques VD; Passos GRD; Mendes MF; Callegaro D; Lana-Peixoto MA; Comini-Frota ER; Vasconcelos CCF; Sato DK; Ferreira MLB; Parolin MKF; Damasceno A; Grzesiuk AK; Muniz A; Matta APDC; Oliveira BES; Tauil CB; Maciel DRK; Diniz DS; Corrêa EC; Coronetti F; Jorge FMH; Sato HK; Gonçalves MVM; Sousa NAC; Nascimento OJM; Gama PDD; Domingues R; Simm RF; Thomaz RB; Morales RR; Dias RM; Apóstolos-Pereira SD; Machado SCN; Junqueira TF; Becker J
    Arq Neuropsiquiatr; 2018 Aug; 76(8):539-554. PubMed ID: 30231128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis.
    Krysko KM; Graves JS; Rensel M; Weinstock-Guttman B; Rutatangwa A; Aaen G; Belman A; Benson L; Chitnis T; Gorman M; Goyal MS; Harris Y; Krupp L; Lotze T; Mar S; Moodley M; Ness J; Rodriguez M; Rose J; Schreiner T; Tillema JM; Waltz M; Casper TC; Waubant E;
    Ann Neurol; 2020 Jul; 88(1):42-55. PubMed ID: 32267005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethical use of off-label disease-modifying therapies for multiple sclerosis.
    Laurson-Doube J; Rijke N; Helme A; Baneke P; Banwell B; Viswanathan S; Hemmer B; Yamout B
    Mult Scler; 2021 Aug; 27(9):1403-1410. PubMed ID: 34304636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
    Chen J; Taylor BV; Blizzard L; Simpson S; Palmer AJ; van der Mei IAF
    J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1200-1207. PubMed ID: 29921609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classifying PML risk with disease modifying therapies.
    Berger JR
    Mult Scler Relat Disord; 2017 Feb; 12():59-63. PubMed ID: 28283109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the efficacy of disease-modifying therapies in multiple sclerosis.
    Mitsikostas DD; Goodin DS
    Mult Scler Relat Disord; 2017 Nov; 18():109-116. PubMed ID: 29141791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of evidence supporting the Federation of Bosnia and Herzegovina reimbursement medicines lists: role of the WHO Essential Medicines List, Cochrane systematic reviews and technology assessment reports.
    Mahmić-Kaknjo M; Marušić A
    Eur J Clin Pharmacol; 2015 Jul; 71(7):825-33. PubMed ID: 25956715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years.
    Setayeshgar S; Kingwell E; Zhu F; Zhang X; Zhang T; Marrie RA; Carruthers R; Tremlett H
    Mult Scler Relat Disord; 2018 Oct; 25():57-60. PubMed ID: 30036855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Essential medicines for emergency care in Africa.
    Broccoli MC; Pigoga JL; Nyirenda M; Wallis L; Calvello Hynes EJ
    Emerg Med J; 2018 Jul; 35(7):412-419. PubMed ID: 29627770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis.
    Eagle T; Stuart F; Chua AS; LaRussa A; Leclaire K; Cook SL; Chitnis T; Weiner HL; Glanz BI; Healy BC
    Mult Scler Relat Disord; 2017 Nov; 18():196-201. PubMed ID: 29141809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.
    Tan H; Cai Q; Agarwal S; Stephenson JJ; Kamat S
    Adv Ther; 2011 Jan; 28(1):51-61. PubMed ID: 21153000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosis.
    Hartung DM; Johnston KA; Geddes J; Bourdette DN
    Neurology; 2020 Mar; 94(13):e1407-e1414. PubMed ID: 31941796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.